Late effects in survivors of infant leukemia.
Little is known about the incidence of and risk factor for late effects of infant leukemia. We evaluated 19 children with acute lymphoblastic leukemia and 15 with acute myeloid leukemia who were diagnosed at age 12 months or younger and have survived for more than 5 years after the diagnosis (median length of follow-up, 13 years; range, 5.7-29 years). Ten patients received chemotherapy alone (group A), 17 received chemotherapy and CNS-directed radiation therapy (CRT) (group B), and seven received chemotherapy, CRT and bone marrow transplantation (group C). The most frequently observed late sequelae included problems in growth (66% of survivors), learning (50%), hypothyroidism (15%), and pubertal development (12%). Cataract, cardiac and hearing abnormalities occurred in 6% of patients. Only eight patients (24%) survive without late effects. In comparison to patients in group A, patients in groups B and C had a higher incidence of having at least one late complication (P = 0.009), a greater decrease in height Z score at 5 years after diagnosis (P = 0.023), and a higher incidence of academic difficulties (P = 0.004). The estimated odds of academic difficulties increased by 18% (P = 0.032) for each month younger in age at the time of CRT. These results indicate that late sequelae are common in longterm survivors of infant leukemia and are often related to CRT and the patient's age at the time of CRT.
Leung
W
W
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Hudson
M
M
Zhu
Y
Y
Rivera
G K
GK
Ribeiro
R C
RC
Sandlund
J T
JT
Bowman
L C
LC
Evans
W E
WE
Kun
L
L
Pui
C H
CH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002291:Carcinoma, Papillary / Q000209:etiology; D002386:Cataract / Q000453:epidemiology / Q000209:etiology; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects*; D003638:Deafness / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D007037:Hypothyroidism / Q000453:epidemiology / Q000209:etiology; D007223:Infant; D007859:Learning Disabilities / Q000453:epidemiology / Q000209:etiology*; D007938:Leukemia / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000209:etiology; D016017:Odds Ratio; D011628:Puberty, Delayed / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D017741:Survivors; D013964:Thyroid Neoplasms / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D018487:Ventricular Dysfunction, Left / Q000453:epidemiology / Q000209:etiology